Helus Pharma Secures $50M Funding as Phase 3 Trial Nears Completion
Event summary
- $50 million underwritten offering bolsters balance sheet for Phase 3 HLP003 trial.
- Phase 3 APPROACH study enrollment surpasses 88%, topline data readout expected in Q4 2026.
- HLP004 Phase 2 signal detection study shows ~10-point improvement from baseline in HAM-A.
- Strengthened leadership team with globally recognized experts in clinical development and medical affairs.
The big picture
Helus Pharma’s recent funding round and clinical trial progress position it as a key player in the mental health biotech space. The company’s focus on serotonergic agonists aligns with growing regulatory support for psychedelic therapies, potentially transforming the treatment landscape for depression and anxiety disorders. With a strengthened leadership team and robust financial backing, Helus Pharma is poised to capitalize on unmet needs in adjunctive therapy for MDD.
What we're watching
- Regulatory Pathway
- Whether the FDA Breakthrough Therapy Designation will expedite HLP003's approval process.
- Clinical Success
- The pace at which Phase 3 APPROACH study results could impact Helus Pharma’s valuation.
- Market Positioning
- How HLP004's Phase 2 data will influence the design of its next study and competitive positioning in GAD treatment.
Related topics